Concepts (214)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Complement System Proteins | 6 | 2000 | 82 | 0.740 |
Why?
|
| Myocardium | 10 | 2007 | 573 | 0.460 |
Why?
|
| Heart | 7 | 2002 | 578 | 0.410 |
Why?
|
| Complement Membrane Attack Complex | 6 | 2000 | 21 | 0.350 |
Why?
|
| Rabbits | 13 | 2000 | 640 | 0.330 |
Why?
|
| Reperfusion Injury | 2 | 2000 | 144 | 0.310 |
Why?
|
| Myocardial Infarction | 4 | 2000 | 380 | 0.310 |
Why?
|
| Complement Activation | 4 | 2000 | 81 | 0.290 |
Why?
|
| In Vitro Techniques | 10 | 2002 | 996 | 0.260 |
Why?
|
| Heart Failure | 10 | 2007 | 1252 | 0.260 |
Why?
|
| Myocardial Ischemia | 5 | 2002 | 162 | 0.250 |
Why?
|
| Ventricular Dysfunction, Left | 7 | 2005 | 332 | 0.240 |
Why?
|
| Intracranial Hemorrhages | 1 | 2024 | 130 | 0.220 |
Why?
|
| Complement Inactivator Proteins | 2 | 2000 | 27 | 0.220 |
Why?
|
| Pentosan Sulfuric Polyester | 2 | 1999 | 7 | 0.210 |
Why?
|
| Gene Expression Regulation | 3 | 2005 | 1983 | 0.200 |
Why?
|
| Ischemic Preconditioning, Myocardial | 1 | 2000 | 12 | 0.180 |
Why?
|
| Complement C5a | 1 | 2000 | 24 | 0.180 |
Why?
|
| Myocytes, Cardiac | 5 | 2014 | 314 | 0.170 |
Why?
|
| Complement Factor D | 1 | 1999 | 3 | 0.170 |
Why?
|
| Complement Pathway, Alternative | 1 | 1999 | 13 | 0.170 |
Why?
|
| Ischemic Preconditioning | 1 | 1999 | 37 | 0.170 |
Why?
|
| Hemodynamics | 7 | 2004 | 738 | 0.160 |
Why?
|
| Chemotaxis | 1 | 1999 | 73 | 0.160 |
Why?
|
| Cocaine | 1 | 2000 | 77 | 0.160 |
Why?
|
| Myocardial Reperfusion Injury | 4 | 2000 | 58 | 0.160 |
Why?
|
| Transcription, Genetic | 2 | 2000 | 1158 | 0.150 |
Why?
|
| Animals | 26 | 2014 | 27516 | 0.150 |
Why?
|
| Potassium Channels | 1 | 1999 | 346 | 0.140 |
Why?
|
| Ventricular Function, Left | 4 | 2007 | 613 | 0.140 |
Why?
|
| Dogs | 10 | 2007 | 706 | 0.130 |
Why?
|
| Cardiomegaly | 2 | 2014 | 120 | 0.130 |
Why?
|
| PTEN Phosphohydrolase | 2 | 2014 | 137 | 0.130 |
Why?
|
| Ventricular Remodeling | 3 | 2007 | 108 | 0.130 |
Why?
|
| RNA, Messenger | 7 | 2007 | 2025 | 0.120 |
Why?
|
| Myocardial Contraction | 4 | 2004 | 252 | 0.120 |
Why?
|
| Phosphatidylinositol 4,5-Diphosphate | 1 | 2014 | 11 | 0.120 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2024 | 2676 | 0.120 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2000 | 885 | 0.110 |
Why?
|
| Electric Stimulation Therapy | 2 | 2004 | 47 | 0.110 |
Why?
|
| Antibodies, Monoclonal | 1 | 1999 | 1394 | 0.110 |
Why?
|
| Actins | 1 | 2014 | 462 | 0.090 |
Why?
|
| Anticoagulants | 3 | 1999 | 431 | 0.090 |
Why?
|
| Myocardial Reperfusion | 2 | 2000 | 28 | 0.090 |
Why?
|
| Angiotensin II | 2 | 2014 | 93 | 0.080 |
Why?
|
| Heparin | 2 | 2000 | 185 | 0.080 |
Why?
|
| Blotting, Western | 2 | 2000 | 793 | 0.080 |
Why?
|
| Anti-Arrhythmia Agents | 2 | 2000 | 65 | 0.080 |
Why?
|
| Male | 11 | 2024 | 42614 | 0.070 |
Why?
|
| Hypoxia | 2 | 2003 | 657 | 0.070 |
Why?
|
| PPAR gamma | 1 | 2007 | 72 | 0.070 |
Why?
|
| Dilatation, Pathologic | 1 | 2005 | 55 | 0.060 |
Why?
|
| Liver | 2 | 2000 | 1211 | 0.060 |
Why?
|
| Stroke Volume | 5 | 2007 | 479 | 0.060 |
Why?
|
| Surgical Mesh | 1 | 2005 | 124 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2007 | 1929 | 0.060 |
Why?
|
| Prosthesis Implantation | 1 | 2005 | 129 | 0.060 |
Why?
|
| Gene Expression | 3 | 2007 | 1309 | 0.060 |
Why?
|
| Implants, Experimental | 1 | 2003 | 16 | 0.060 |
Why?
|
| Signal Transduction | 1 | 2014 | 3403 | 0.060 |
Why?
|
| Neutrophils | 3 | 1999 | 311 | 0.050 |
Why?
|
| Acrylates | 1 | 2003 | 18 | 0.050 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 1 | 2002 | 17 | 0.050 |
Why?
|
| Spironolactone | 1 | 2002 | 12 | 0.050 |
Why?
|
| Thiophenes | 1 | 2003 | 43 | 0.050 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2003 | 39 | 0.050 |
Why?
|
| Metoprolol | 1 | 2002 | 15 | 0.050 |
Why?
|
| Disease Models, Animal | 6 | 2007 | 2392 | 0.050 |
Why?
|
| Pinacidil | 2 | 1999 | 2 | 0.050 |
Why?
|
| Norepinephrine | 1 | 2003 | 172 | 0.050 |
Why?
|
| Thiorphan | 1 | 2002 | 5 | 0.050 |
Why?
|
| Chronic Disease | 5 | 2003 | 958 | 0.050 |
Why?
|
| Sheep | 2 | 1999 | 251 | 0.050 |
Why?
|
| Neprilysin | 1 | 2002 | 41 | 0.050 |
Why?
|
| Vasodilator Agents | 2 | 2000 | 145 | 0.050 |
Why?
|
| Caspases | 1 | 2002 | 155 | 0.050 |
Why?
|
| Imidazoles | 1 | 2003 | 140 | 0.050 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2002 | 105 | 0.050 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2024 | 474 | 0.050 |
Why?
|
| Heart Ventricles | 2 | 2003 | 786 | 0.050 |
Why?
|
| Hydroxy Acids | 1 | 2000 | 9 | 0.050 |
Why?
|
| Decanoic Acids | 1 | 2000 | 11 | 0.050 |
Why?
|
| Diazoxide | 1 | 2000 | 19 | 0.050 |
Why?
|
| Complement C8 | 1 | 2000 | 1 | 0.050 |
Why?
|
| Complement C9 | 1 | 2000 | 3 | 0.050 |
Why?
|
| Xanthine | 1 | 2000 | 6 | 0.050 |
Why?
|
| Receptors, Complement 3b | 1 | 2000 | 39 | 0.050 |
Why?
|
| Complement C1q | 1 | 2000 | 11 | 0.050 |
Why?
|
| Xanthine Oxidase | 1 | 2000 | 25 | 0.040 |
Why?
|
| Hemolysis | 1 | 2000 | 64 | 0.040 |
Why?
|
| Complement C3 | 1 | 2000 | 58 | 0.040 |
Why?
|
| Free Radicals | 1 | 2000 | 71 | 0.040 |
Why?
|
| Receptors, Complement | 1 | 2000 | 46 | 0.040 |
Why?
|
| Tiopronin | 1 | 2000 | 6 | 0.040 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 3 | 2007 | 125 | 0.040 |
Why?
|
| Cell Size | 2 | 2014 | 69 | 0.040 |
Why?
|
| Procaine | 1 | 2000 | 11 | 0.040 |
Why?
|
| Glyburide | 1 | 1999 | 32 | 0.040 |
Why?
|
| Heparin Lyase | 1 | 1999 | 4 | 0.040 |
Why?
|
| Heparin Antagonists | 1 | 1999 | 3 | 0.040 |
Why?
|
| Solubility | 1 | 2000 | 184 | 0.040 |
Why?
|
| Heart Diseases | 1 | 2002 | 301 | 0.040 |
Why?
|
| Potassium Channel Blockers | 1 | 1999 | 64 | 0.040 |
Why?
|
| Ligation | 1 | 1999 | 52 | 0.040 |
Why?
|
| Endotoxins | 1 | 1999 | 36 | 0.040 |
Why?
|
| Apoptosis | 2 | 2003 | 1717 | 0.040 |
Why?
|
| Drug Interactions | 1 | 2000 | 244 | 0.040 |
Why?
|
| Glycosaminoglycans | 1 | 1999 | 47 | 0.040 |
Why?
|
| Luteinizing Hormone | 1 | 1999 | 167 | 0.040 |
Why?
|
| Blood Platelets | 1 | 1999 | 150 | 0.040 |
Why?
|
| DNA Primers | 1 | 1999 | 543 | 0.040 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2003 | 480 | 0.040 |
Why?
|
| Cell Movement | 2 | 1999 | 786 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 1999 | 374 | 0.040 |
Why?
|
| Perfusion | 1 | 2000 | 253 | 0.040 |
Why?
|
| Erythrocytes | 1 | 1999 | 254 | 0.040 |
Why?
|
| Enzyme Activation | 2 | 2014 | 696 | 0.040 |
Why?
|
| Electrocardiography | 2 | 2003 | 497 | 0.040 |
Why?
|
| Estradiol | 1 | 1999 | 250 | 0.040 |
Why?
|
| Complement C6 | 1 | 1998 | 1 | 0.040 |
Why?
|
| Glycyrrhizic Acid | 1 | 1998 | 1 | 0.040 |
Why?
|
| Recombinant Proteins | 1 | 2000 | 1008 | 0.040 |
Why?
|
| Interleukin-8 | 1 | 1998 | 86 | 0.040 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 1997 | 30 | 0.040 |
Why?
|
| Time Factors | 3 | 2003 | 5357 | 0.040 |
Why?
|
| Coronary Vessels | 1 | 1999 | 192 | 0.040 |
Why?
|
| Antibodies | 1 | 1999 | 353 | 0.040 |
Why?
|
| Up-Regulation | 1 | 2000 | 726 | 0.040 |
Why?
|
| Proteins | 1 | 2002 | 786 | 0.030 |
Why?
|
| Cyclopropanes | 1 | 1996 | 25 | 0.030 |
Why?
|
| Enzyme Inhibitors | 1 | 1999 | 644 | 0.030 |
Why?
|
| Fibrinolytic Agents | 1 | 1997 | 227 | 0.030 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 1996 | 91 | 0.030 |
Why?
|
| Disease Progression | 3 | 2005 | 1469 | 0.030 |
Why?
|
| Humans | 8 | 2024 | 89864 | 0.030 |
Why?
|
| Phosphatidylinositol Phosphates | 1 | 2014 | 15 | 0.030 |
Why?
|
| Subcellular Fractions | 1 | 2014 | 94 | 0.030 |
Why?
|
| Creatine Kinase | 3 | 1999 | 52 | 0.030 |
Why?
|
| Fibroblast Growth Factor 2 | 2 | 2005 | 57 | 0.030 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2007 | 165 | 0.030 |
Why?
|
| Echocardiography | 3 | 2004 | 944 | 0.030 |
Why?
|
| Aged, 80 and over | 1 | 2024 | 6779 | 0.030 |
Why?
|
| Administration, Oral | 2 | 2007 | 666 | 0.030 |
Why?
|
| Cardiac Catheterization | 2 | 2005 | 307 | 0.030 |
Why?
|
| Heart Rate | 2 | 2007 | 498 | 0.030 |
Why?
|
| Models, Cardiovascular | 2 | 2003 | 107 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2003 | 226 | 0.030 |
Why?
|
| Models, Animal | 2 | 2004 | 277 | 0.020 |
Why?
|
| Coronary Angiography | 2 | 2004 | 243 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2014 | 1237 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2024 | 9185 | 0.020 |
Why?
|
| Middle Aged | 2 | 2024 | 26103 | 0.020 |
Why?
|
| Rats | 1 | 2014 | 4048 | 0.020 |
Why?
|
| Peroxidase | 2 | 1998 | 51 | 0.020 |
Why?
|
| Adult | 2 | 2024 | 26784 | 0.020 |
Why?
|
| Female | 4 | 2024 | 46529 | 0.020 |
Why?
|
| Leukocyte Count | 2 | 1998 | 224 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2014 | 3250 | 0.020 |
Why?
|
| Aged | 1 | 2024 | 19230 | 0.020 |
Why?
|
| Atrial Natriuretic Factor | 1 | 2007 | 39 | 0.020 |
Why?
|
| Organ Size | 1 | 2007 | 372 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2007 | 268 | 0.020 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2005 | 18 | 0.020 |
Why?
|
| Follow-Up Studies | 2 | 2003 | 3670 | 0.020 |
Why?
|
| Protein Kinases | 1 | 2007 | 212 | 0.020 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-2 | 1 | 2005 | 24 | 0.020 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2005 | 48 | 0.020 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2007 | 188 | 0.020 |
Why?
|
| Body Weight | 1 | 2007 | 453 | 0.020 |
Why?
|
| Manometry | 1 | 2004 | 44 | 0.010 |
Why?
|
| Ventricular Myosins | 1 | 2003 | 4 | 0.010 |
Why?
|
| Calcium-Transporting ATPases | 1 | 2003 | 29 | 0.010 |
Why?
|
| Sarcoplasmic Reticulum Calcium-Transporting ATPases | 1 | 2003 | 25 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2005 | 405 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 2003 | 68 | 0.010 |
Why?
|
| Microspheres | 1 | 2003 | 108 | 0.010 |
Why?
|
| Immunohistochemistry | 2 | 1998 | 1799 | 0.010 |
Why?
|
| Receptors, Angiotensin | 1 | 2003 | 12 | 0.010 |
Why?
|
| Fas Ligand Protein | 1 | 2003 | 49 | 0.010 |
Why?
|
| Receptor, Angiotensin, Type 1 | 1 | 2003 | 21 | 0.010 |
Why?
|
| Calcium-Binding Proteins | 1 | 2003 | 121 | 0.010 |
Why?
|
| Ventricular Pressure | 1 | 2003 | 41 | 0.010 |
Why?
|
| Cyclin D1 | 1 | 2003 | 84 | 0.010 |
Why?
|
| Cytokines | 1 | 2007 | 811 | 0.010 |
Why?
|
| Stress, Mechanical | 1 | 2003 | 253 | 0.010 |
Why?
|
| Electric Stimulation | 1 | 2003 | 365 | 0.010 |
Why?
|
| Muscle Fibers, Skeletal | 1 | 2002 | 50 | 0.010 |
Why?
|
| Caspase 3 | 1 | 2002 | 162 | 0.010 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2002 | 101 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2005 | 869 | 0.010 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2002 | 198 | 0.010 |
Why?
|
| Fibrosis | 1 | 2002 | 236 | 0.010 |
Why?
|
| Membrane Glycoproteins | 1 | 2003 | 431 | 0.010 |
Why?
|
| Mice | 1 | 2014 | 11846 | 0.010 |
Why?
|
| Treatment Outcome | 2 | 2003 | 8264 | 0.010 |
Why?
|
| Lanthanum | 1 | 1999 | 16 | 0.010 |
Why?
|
| Iodine Radioisotopes | 1 | 1999 | 134 | 0.010 |
Why?
|
| Body Temperature | 1 | 1999 | 125 | 0.010 |
Why?
|
| Progesterone | 1 | 1999 | 110 | 0.010 |
Why?
|
| Calcium | 1 | 2003 | 1179 | 0.010 |
Why?
|
| Incidence | 1 | 2003 | 1600 | 0.010 |
Why?
|
| P-Selectin | 1 | 1998 | 13 | 0.010 |
Why?
|
| Complement C3 Convertase, Alternative Pathway | 1 | 1997 | 1 | 0.010 |
Why?
|
| Complement C3b | 1 | 1997 | 5 | 0.010 |
Why?
|
| Hydrocortisone | 1 | 1999 | 301 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 1997 | 303 | 0.010 |
Why?
|
| Glycoproteins | 1 | 1998 | 235 | 0.010 |
Why?
|
| Cell Adhesion | 1 | 1998 | 426 | 0.010 |
Why?
|
| Guanidines | 1 | 1996 | 31 | 0.010 |
Why?
|
| Stereoisomerism | 1 | 1996 | 102 | 0.010 |
Why?
|
| Ventricular Fibrillation | 1 | 1996 | 68 | 0.010 |
Why?
|
| Peptide Fragments | 1 | 1997 | 463 | 0.010 |
Why?
|
| Cardiomyopathies | 1 | 1997 | 266 | 0.010 |
Why?
|
| Blood Pressure | 1 | 1998 | 905 | 0.010 |
Why?
|